Skip to main content

Table 1 Reasons for premature discontinuation

From: Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch

 

Number of patients (%)

 

Titration (n = 295)

Year 1 (n = 290)

Year 2 (n = 220)

Patients withdrawn

5 (1.7)

70 (24.1)

29 (13.2)

Owing to

   

Adverse event

4 (1.4)

47 (16.2)

16 (7.3)

Withdrawal of consent

1 (0.3)

6 (2.1)

2 (0.9)

Lack of efficacy

0

10 (3.5)

7 (3.2)

Protocol deviation

0

4 (1.4)

0

Unsatisfactory compliance

0

2 (0.7)

2 (0.9)

Lost to follow-up

0

1 (0.3)

0

Other reasons

0

0

2 (0.9)